{"references": ["Benchimol JL. Leishmaniases of the New World from a historical and global perspective, from the 1930s to the 1960s. Hist Cienc Saude Manguinhos [Internet]. 2020;27(Suppl 1):95-122. Disponible en: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-59702020000900095&lng=en&nrm=iso&tlng=en. DOI: 10.1590/S0104-59702020000300006 PMID 32997059", "Alvar J, V\u00e9lez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS One [Internet]. 2012;7(5):e35671. Disponible en: https://doi.org/10.1371/journal.pone.0035671. DOI: 10.1371/journal.pone.0035671 PMID 22693548 PMCID: PMC3365071", "Ram\u00edrez JD, Hern\u00e1ndez C, Le\u00f3n CM, Ayala MS, Fl\u00f3rez C, Gonz\u00e1lez C. Taxonomy, diversity, temporal and geographical distribution of Cutaneous Leishmaniasis in Colombia: A retrospective study. Sci Rep [Internet]. 2016;6(1):28266. Disponible en: https://doi.org/10.1038/srep28266. DOI: 10.1038/srep28266. PMID 27328969 PMCID: PMC4916406", "Instituto Nacional de Salud. Bolet\u00edn Epidemiol\u00f3gico Semanal. Leishmaniasis. Semana Epidemiol\u00f3gica 41, 6 al 12 de octubre de 2019 [Internet]. 2019. Disponible en: https://www.ins.gov.co/buscador-eventos/BoletinEpidemiologico/2019_Boletin_epidemiologico_semana_41.pdf", "Modabber F, Buffet PA, Torreele E, Milon G, Croft SL. Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13\u201315 June, 2006. Kinetoplastid Biol Dis [Internet]. 2007;6(1):3. Disponible en: https://doi.org/10.1186/1475-9292-6-3. DOI: 10.1186/1475-9292-6-3 PMID 17456237 PMCID PMC1868746", "Chakravarty J, Sundar S. Drug resistance in leishmaniasis. J Glob Infect Dis [Internet]. 2010;2(2):167-76. Disponible en: https://www.jgid.org/article.asp?issn=0974-777X. DOI: 10.4103/0974-777X.62887 PMID 20606973 PMCID PMC2889657", "Cardona-Arias JA, L\u00f3pez-Carvajal L, Tamayo Plata MP, V\u00e9lez ID. Cost-effectiveness analysis of thermotherapy versus pentavalent antimonials for the treatment of cutaneous leishmaniasis. J Evid Based Med [Internet]. 2017;10(2):81-90. Disponible en: https://doi.org/10.1111/jebm.12245. DOI: 10.1111/jebm.12245 PMID 28276641", "Gore Saravia N, Nicholls RS. Leishmaniasis: un reto para la salud p\u00fablica que exige concertaci\u00f3n de voluntades y esfuerzos. Biom\u00e9dica [Internet]. 2006;26(Sup1):5-9. Disponible en: https://revistabiomedica.org/index.php/biomedica/article/view/1493. DOI: 10.7705/biomedica.v26i1.1493 PMID 17361835", "Scorza BM, Carvalho EM, Wilson ME. Cutaneous Manifestations of Human and Murine Leishmaniasis. Int J Mol Sci [Internet]. 2017;18(6):1296. Disponible en: https://www.mdpi.com/1422-0067/18/6/1296. DOI: 10.3390/ijms18061296 PMID 28629171 PMCID PMC5486117", "Villa-Pulgar\u00edn JA, Gajate C, Botet J, Jimenez A, Justies N, Varela-M RE, et al. Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine. PLoS Negl Trop Dis [Internet]. 2017;11(8):e0005805. Disponible en: https://doi.org/10.1371/journal.pntd.0005805. DOI: 10.1371/journal.pntd.0005805 PMID 28829771 PMCID PMC5568728", "Dar MJ, Din FU, Khan GM. Sodium stibogluconate loaded nano-deformable liposomes for topical treatment of leishmaniasis: macrophage as a target cell. Drug Deliv [Internet]. 2018;25(1):1595-606. Disponible en: https://doi.org/10.1080/10717544.2018.1494222. DOI: 10.1080/10717544.2018.1494222 PMID 30105918 PMCID PMC6095017", "Neira LF, Pe\u00f1a DP, Vera AM, Mantilla JC, Escobar P. Leishmaniasis cut\u00e1nea inducida por especies de Leishmania Viannia en ratones BALB/c y eficacia de un tratamiento t\u00f3pico. Rev la Univ Ind Santander Salud [Internet]. 2019;51(1):33-42. Disponible en: https://revistas.uis.edu.co/index.php/revistasaluduis/article/view/9209. DOI: 10.18273/revsal.v51n1-2019004", "Berenguer D, Alcover MM, Sessa M, Halbaut L, Guill\u00e9n C, Boix-Monta\u00f1\u00e9s A, et al. Topical Amphotericin B Semisolid Dosage Form for Cutaneous Leishmaniasis: Physicochemical Characterization, Ex Vivo Skin Permeation and Biological Activity. Pharmaceutics [Internet]. 2020;12(2):149. Disponible en: https://www.mdpi.com/1999-4923/12/2/149. DOI: 10.3390/pharmaceutics12020149 PMID 32059430 PMCID PMC7076632", "Mostafavi M, Sharifi I, Farajzadeh S, Khazaeli P, Sharifi H, Pourseyedi E, et al. Niosomal formulation of amphotericin B alone and in combination with glucantime: In vitro and in vivo leishmanicidal effects. Biomed Pharmacother [Internet]. 2019;116:108942. Disponible en: https://www.sciencedirect.com/science/article/pii/S0753332219313939. DOI: 10.1016/j.biopha.2019.108942 PMID 31152929", "Eskandari SE, Firooz A, Nassiri-Kashani M, Jaafari MR, Javadi A, Miramin-Mohammadi A, et al. Safety Evaluation of Nano-Liposomal Formulation of Amphotericin B (SinaAmpholeish) in Animal Model as a Candidate for Treatment of Cutaneous Leishmaniasis. J Arthropod Borne Dis [Internet]. 2018;12(3):269-75. Disponible en: https://jad.tums.ac.ir/index.php/jad/article/view/943 PMID: 30584550 PMCID PMC6297728", "Dalimi A, Delavari M, Ghaffarifar F, Sadraei J. In vitro and in vivo antileishmanial effects of aloe-emodin on Leishmania major. J Tradit Complement Med [Internet]. 2015;5(2):96-9. Disponible en: https://www.sciencedirect.com/science/article/pii/S2225411014000145. DOI: 10.1016/j.jtcme.2014.11.004 PMID 26151018 PMCID PMC4488107", "Van Bocxlaer K, Caridha D, Black C, Vesely B, Leed S, Sciotti RJ, et al. Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis. Int J Parasitol Drugs Drug Resist [Internet]. 2019;11:129-38. Disponible en: https://www.sciencedirect.com/science/article/pii/S2211320718301854. DOI: 10.1016/j.ijpddr.2019.02.002 PMID 30922847 PMCID PMC6904836", "Parihar SP, Hartley M-A, Hurdayal R, Guler R, Brombacher F. Topical Simvastatin as Host-Directed Therapy against Severity of Cutaneous Leishmaniasis in Mice. Sci Rep [Internet]. 2016;6(1):33458. Disponible en: https://doi.org/10.1038/srep33458 DOI: 10.1038/srep33458. PMID 27632901 PMCID PMC5025842", "Metwally DM, Al-Olayan EM, El-Khadragy MF, Alkathiri B. Anti-Leishmanial Activity (In Vitro and In Vivo) of Allicin and Allicin Cream Using Leishmania major (Sub-strain Zymowme LON4) and Balb/c Mice. PLoS One [Internet]. 2016;11(8):e0161296. Disponible en: https://doi.org/10.1371/journal.pone.0161296. DOI: 10.1371/journal.pone.0161296 PMID 27537199 PMCID PMC4990270", "Peniche AG, Renslo AR, Melby PC, Travi BL. Antileishmanial Activity of Disulfiram and Thiuram Disulfide Analogs in an Ex Vivo Model System Is Selectively Enhanced by the Addition of Divalent Metal Ions. Antimicrob Agents Chemother [Internet]. 2021;59(10):6463-70. Disponible en: https://doi.org/10.1128/AAC.05131-14. DOI: 10.1128/AAC.05131-14 PMID: 26239994 PMCID PMC4576107", "Lezama-D\u00e1vila CM, McChesney JD, Bastos JK, Miranda MA, Tiossi RF, da Costa J de C, et al. A New Antileishmanial Preparation of Combined Solamargine and Solasonine Heals Cutaneous Leishmaniasis through Different Immunochemical Pathways. Antimicrob Agents Chemother [Internet]. 2021;60(5):2732-8. Disponible en: https://doi.org/10.1128/AAC.02804-15. DOI: 10.1128/AAC.02804-15 PMID 26883711 PMCID PMC4862480", "Ghaffarpasand F, Akbarzadeh A, Heiran HR, Karimi AA, Akbarzadeh A, Ghobadifar MA. Effect of topical morphine on cutaneous leishmaniasis in an animal model: A preliminary report. Iran Red Crescent Med J [Internet]. 2016;18(5):24402. Disponible en: https://www.sid.ir/en/journal/ViewPaper.aspx?ID=512685. DOI: 10.5812/ircmj.24402 PMID 27437123 PMCID PMC4939412", "Mu\u00f1oz BY, Mantilla JC, Escobar P. Therapeutic response and safety of the topical, sequential use of antiseptic, keratolytic, and pentamidine creams (3-PACK) on Leishmania (viannia) braziliensis-infected mice. Mem Inst Oswaldo Cruz [Internet]. 2019;114(3):180535. Disponible en: https://www.scielo.br/j/mioc/a/V8htqKRxfVF8g5Kv4f3bHzG/?lang=en. DOI: 10.1590/0074-02760180535 PMID 31090861 PMCID: PMC6516740", "Artzi O, Sprecher E, Koren A, Mehrabi JN, Katz O, Hilerowicz Y. Fractional ablative CO2 laser followed by topical application of sodium stibogluconate for treatment of active cutaneous leishmaniasis: A randomized controlled trial. Acta Derm Venereol [Internet]. 2018;99(1):53-7. Disponible en: https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3058. DOI: 10.2340/00015555-3058. PMID 30281141", "Jaffary F, Nilforoushzadeh MA, Siadat A, Haftbaradaran E, Ansari N, Ahmadi E. A Comparison between the Effects of Glucantime, Topical Trichloroacetic Acid 50% plus Glucantime, and Fractional Carbon Dioxide Laser plus Glucantime on Cutaneous Leishmaniasis Lesions. Dermatol Res Pract [Internet]. 2016;2016:6462804. Disponible en: https://doi.org/10.1155/2016/6462804. DOI: 10.1155/2016/6462804 PMID 27148363 PMCID PMC4842369", "Machado PRL, Ribeiro CS, Fran\u00e7a-Costa J, Dourado MEF, Trinconi CT, Yokoyama-Yasunaka JKU, et al. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial. Trop Med Int Heal [Internet]. 2018;23(9):936-42. Disponible en: https://doi.org/10.1111/tmi.13119. DOI: 10.1111/tmi.13119 PMID 29924907", "L\u00f3pez L, V\u00e9lez I, Asela C, Cruz C, Alves F, Robledo S, et al. A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia. PLoS Negl Trop Dis [Internet]. 2018;12(7):e0006653. Disponible en: https://doi.org/10.1371/journal.pntd.0006653. DOI: 10.1371/journal.pntd.0006653 PMID 30044792 PMCID PMC6078324", "Asilian A, Sadeghinia A, Faghihi G, Momeni A. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime\u00ae) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime\u00ae) alone for the treatment of cutaneous leishmaniasis. Int J Dermatol [Internet]. 2004;43(4):281-3. Disponible en: https://doi.org/10.1111/j.1365-4632.2004.02002.x. DOI: 10.1111/j.1365-4632.2004.02002.x PMID 15090013", "Uzun S, Durdu M, Culha G, Allahverdiyev AM, Memisoglu HR. Clinical Features, Epidemiology, and Efficacy and Safety of Intralesional Antimony Treatment of Cutaneous Leishmaniasis: Recent Experience In Turkey. J Parasitol [Internet]. 2004;90(4):853-9. Disponible en: https://doi.org/10.1645/GE-185R. DOI: 10.1645/GE-185R PMID 15357081", "L\u00f3pez-Carvajal L, Cardona-Arias JA, Zapata-Cardona MI, S\u00e1nchez-Giraldo V, V\u00e9lez ID. Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: meta-analyses of clinical trials. BMC Infect Dis [Internet]. 2016;16(1):360. Disponible en: https://doi.org/10.1186/s12879-016-1663-3. DOI: 10.1186/s12879-016-1663-3 PMID 27456008 PMCID PMC4960741", "Sepaskhah M, Behdad K, Bagheri Z. The topical treatment of old world cutaneous leishmaniasis with gentian violet along with cryotherapy: A pilot single-blind randomized controlled clinical trial. Rev Soc Bras Med Trop [Internet]. 2019;52:e20180278. Disponible en: https://www.scielo.br/j/rsbmt/a/7vKBZTJrt8kqMf3mbtR86dg/?lang=en. DOI: 10.1590/0037-8682-0278-2018 PMID 30994790", "Parvizi MM, Handjani F, Moein M, Hatam G, Nimrouzi M, Hassanzadeh J, et al. Efficacy of cryotherapy plus topical Juniperus excelsa M. Bieb cream versus cryotherapy plus placebo in the treatment of Old World cutaneous leishmaniasis: A triple-blind randomized controlled clinical trial. PLoS Negl Trop Dis [Internet]. 2017;11(10):e0005957. Disponible en: https://doi.org/10.1371/journal.pntd.0005957. DOI: 10.1371/journal.pntd.0005957 PMID 28981503 PMCID PMC5655399", "Molkara S, Poursoltani E, Stahl K-W, Maleki M, Khamesipour A, Bogdan C, et al. Salvage therapy with Sodium chlorosum (formerly DAC N-055) for cases of refractory lupoid cutaneous leishmaniasis: results from a compassionate use study with 0.09% Sodium chlorosum in amphiphilic basic cream. BMC Infect Dis [Internet]. 2019;19(1):1005. Disponible en: https://doi.org/10.1186/s12879-019-4518-x. DOI: 10.1186/s12879-019-4518-x PMID 31779597 PMCID PMC6883658"]}

La leishmaniasis comprende un grupo de enfermedades causadas por parásitos protozoos del género Leishmania transmitidas por la picadura de un insecto vector hematófago. Este complejo grupo de enfermedades dependiendo de la especie de Leishmania infectante y del sistema inmune del hospedador, pueden causar desde lesiones cutáneas ulcerativas, lesiones muco-cutáneas desfigurantes, hasta una forma visceral causando la muerte. La principal herramienta en el tratamiento de las diferentes formas clínicas de la leishmaniasis han sido los antimoniales pentavalentes en dosis de 20 mg/kg por día, por 20 días con una eficacia cercana al 85%. Este tratamiento es doloroso y altamente tóxico, muchos pacientes no lo concluyen, lo que favorece la reactivación de la lesión, el compromiso en mucosas y la aparición de resistencia. En ese sentido, se busca que uno de los tratamientos para las lesiones cutáneas sea aplicado de forma tópica, sin embargo, hasta la fecha este tratamiento aún está en estudio. En este trabajo se ha realizado una revisión sobre los ensayos preclínicos y clínicos de tratamientos tópicos para la Leishmaniasis Cutánea en las bases de datos “Lilacs y Pubmed” teniendo 36 artículos para la revisión total y encontrando una eficiencia en la mayoría de ellos.